Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Laboratory Medicine

Official Journal of the German Society of Clinical Chemistry and Laboratory Medicine

Editor-in-Chief: Schuff-Werner, Peter

Ed. by Ahmad-Nejad, Parviz / Bidlingmaier, Martin / Bietenbeck, Andreas / Conrad, Karsten / Findeisen, Peter / Fraunberger, Peter / Ghebremedhin, Beniam / Holdenrieder, Stefan / Kiehntopf, Michael / Klein, Hanns-Georg / Kohse, Klaus P. / Kratzsch, Jürgen / Luppa, Peter B. / Meyer, Alexander von / Nebe, Carl Thomas / Orth, Matthias / Röhrig-Herzog, Gabriele / Sack, Ulrich / Steimer, Werner / Weber, Thomas / Wieland, Eberhard / Winter, Christoph / Zettl, Uwe K.


IMPACT FACTOR 2018: 0.389

CiteScore 2018: 0.22

SCImago Journal Rank (SJR) 2018: 0.156
Source Normalized Impact per Paper (SNIP) 2018: 0.089

Online
ISSN
2567-9449
See all formats and pricing
More options …
Volume 38, Issue 2

Issues

An update on therapeutic drug monitoring and pharmacogenetic testing for the optimization of therapy with psychiatric medication

Katharina M. Rentsch
  • Corresponding author
  • Clinical Chemistry, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland, Phone: +0041-61-265-42-36, Fax: +0041-61-265-53-33
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2016-06-14 | DOI: https://doi.org/10.1515/labmed-2014-0032

Abstract

Therapeutic drug monitoring of psychiatric medication as well as pharmacogenetic testing is performed more and more frequently in numerous laboratories. In this review, a summary of the literature in the years 2011 and 2012 has been completed. The guidelines of the German AGNP (Association for Neuropsychopharmacology and Pharmacopsychiatry) contain all the information needed for the interpretation of drug concentrations. The determination of serotonin in urine could be a marker for the assessment of the response of antidepressants, and correlations between the occupancy of the target receptors in the brain and drug concentration have been established using positron emission tomography. The influence of age on drug concentrations has been controversially described, and additionally females have always showed a slower metabolism and higher serum concentrations. Several liquid chromatography-mass spectrometry (LC-MS)/MS multi-analyte procedures for the quantification of psychiatric medication have been described. All methods showed good validation data, but there have always been some compounds with less good validation results due to the fact that not all compounds of a multi-analyte procedure can be analyzed optimally. Pharmacogenetic testing is not routinely performed prior to the prescription of psychiatric medication. This relies, among other things, on missing large randomized trials and the absence of standardized analytical methods, which allow the identification of the whole genetic variability.

Keywords: antidepressants; antipsychotic drugs; cytochrome; pharmacogenetics; psychiatric medication

References

  • 1.

    Rentsch K.Therapeutic drug monitoring und drugs of abuse testing. In: Renz H, Neumaier M, von Eckardstein A, editors. Diagnostik Update 2013. Wiesbaden: medupdate GmbH, 2013:1–30.Google Scholar

  • 2.

    Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011;44:195–235.Web of ScienceGoogle Scholar

  • 3.

    Patteet L, Morrens M, Maudens KE, Niemegeers P, Sabbe B, Neels H. Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit 2012;34:629–51.Web of ScienceGoogle Scholar

  • 4.

    Hiemke C, Pfuhlmann B. Interactions and monitoring of antipsychotic drugs. Handb Exp Pharmacol 2012:241–65.Google Scholar

  • 5.

    Nichkova MI, Huisman H, Wynveen PM, Marc DT, Olson KL, Kellermann GH. Evaluation of a novel ELISA for serotonin: urinary serotonin as a potential biomarker for depression. Anal Bioanal Chem 2012;402:1593–600.Web of ScienceGoogle Scholar

  • 6.

    Grunder G, Hiemke C, Paulzen M, Veselinovic T, Vernaleken I. Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging. Pharmacopsychiatry 2011;44:236–48.Web of ScienceGoogle Scholar

  • 7.

    Unterecker S, Riederer P, Proft F, Maloney J, Deckert J, Pfuhlmann B. Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions. J Neural Transm 2013;120:1237–46.Web of ScienceGoogle Scholar

  • 8.

    Waade RB, Molden E, Refsum H, Hermann M. Serum concentrations of antidepressants in the elderly. Ther Drug Monit 2012;34:25–30.Web of ScienceGoogle Scholar

  • 9.

    Couturier PL, Zahr N, Goldwirt L, Warot D, Allilaire JF, Lambrey S. Therapeutic drug monitoring of clomipramine and amitriptyline in a depressed patient with upper digestive tract resection. Ther Drug Monit 2011;33:467–8.Google Scholar

  • 10.

    del Mar Ramirez Fernandez M, Wille SM, Samyn N. Quantitative method validation for the analysis of 27 antidepressants and metabolites in plasma with ultraperformance liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2012;34: 11–24.Google Scholar

  • 11.

    Ansermot N, Brawand-Amey M, Eap CB. Simultaneous quantification of selective serotonin reuptake inhibitors and metabolites in human plasma by liquid chromatography-electrospray mass spectrometry for therapeutic drug monitoring. J Chromatogr B Analyt Technol Biomed Life Sci 2012;885-886:117–30.Google Scholar

  • 12.

    Vecchione G, Casetta B, Chiapparino A, Bertolino A, Tomaiuolo M, Cappucci F, et al. A reliable and rapid tool for plasma quantification of 18 psychotropic drugs by ESI tandem mass spectrometry. J Pharm Biomed Anal 2012;67-68:104–13.Google Scholar

  • 13.

    Hasselstrom J. Quantification of antidepressants and antipsychotics in human serum by precipitation and ultra high pressure liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:123–8.Google Scholar

  • 14.

    Lombard J, Doraiswamy PM. What is the role of pharmacogenetics in clinical psychiatry? Expert Opin Drug Metab Toxicol 2013;9:1–4.Google Scholar

  • 15.

    Malhotra AK, Zhang JP, Lencz T. Pharmacogenetics in psychiatry: translating research into clinical practice. Mol Psychiatry 2012;17:760–9.Web of ScienceGoogle Scholar

  • 16.

    Zhang JP, Malhotra A K. Pharmacogenetics of antipsychotics: recent progress and methodological issues. Expert Opin Drug Metab Toxicol 2013;9:183–91.Google Scholar

  • 17.

    Muller DJ, Brandl EJ, Hwang R, Tiwari AK, Sturgess JE, Zai CC, et al. The AmpliChip(R) CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genet Test Mol Biomarkers 2012;16:897–903.Web of ScienceGoogle Scholar

  • 18.

    Dobrinas M, Cornuz J, Pedrido L, Eap CB. Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking. Pharmacogenet Genomics 2012;22:143–51.Web of ScienceGoogle Scholar

About the article

Received: 2013-09-28

Accepted: 2014-01-28

Published Online: 2016-06-14


Citation Information: LaboratoriumsMedizin, Volume 38, Issue 2, ISSN (Online) 1439-0477, ISSN (Print) 0342-3026, DOI: https://doi.org/10.1515/labmed-2014-0032.

Export Citation

©2016 by De Gruyter.Get Permission

Comments (0)

Please log in or register to comment.
Log in